$elv 2023 Q1 10-K

Concept	2023 Q1	2022 Q4	2022
Revenue	$42.17B	$39.93B	$156.6B
YoY Change	10.7%	9.15%	12.95%
Cost Of Revenue	$3.481B		$13.04B
YoY Change	20.74%		19.64%
Gross Profit	$38.69B		$143.6B
YoY Change	9.88%		12.38%
Gross Profit Margin	91.75%		91.68%
Selling, General & Admin	$4.800B	$4.562B	$17.69B
YoY Change	10.57%	19.71%	11.13%
% of Gross Profit	12.41%		12.32%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$462.0M	$473.0M	$1.675B
YoY Change	29.05%	31.39%	1131.62%
% of Gross Profit	1.19%		1.17%
Operating Expenses	$4.800B	$38.55B	$148.0B
YoY Change	10.57%	11.55%	829.84%
Operating Profit	$2.831B		$8.452B
YoY Change	15.69%		12.86%
Interest Expense	$251.0M	-$229.0M	-$851.0M
YoY Change	24.88%	14.5%	-206.64%
% of Operating Profit	8.87%		-10.07%
Other Income/Expense, Net
YoY Change
Pretax Income	$2.619B	$1.154B	$7.769B
YoY Change	12.6%	-17.57%	-1.97%
Income Tax	$615.0M	$193.0M	$1.750B
% Of Pretax Income	23.48%	16.72%	22.53%
Net Earnings	$1.989B	$949.0M	$6.025B
YoY Change	10.19%	-16.53%	-1.29%
Net Earnings / Revenue	4.72%	2.38%	3.85%
Basic Earnings Per Share	$8.37		$25.10
Diluted Earnings Per Share	$8.30	$3.934M	$24.81M
COMMON SHARES
Basic Shares Outstanding	237.5M shares	238.8M shares	240.0M shares
Diluted Shares Outstanding	239.7M shares		242.8M shares

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.78B	$33.34B
YoY Change	16.67%	7.04%
Cash & Equivalents	$10.14B	$7.387B	$7.387B
Short-Term Investments	$27.64B	$25.95B
Other Short-Term Assets	$4.943B	$5.281B
YoY Change	-4.81%	13.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$59.82B	$55.62B
YoY Change	11.0%	8.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.418B	$4.316B	$4.316B
YoY Change	10.84%	10.13%	-5.08%
Goodwill	$25.27B	$24.38B
YoY Change	4.21%	0.64%
Intangibles	$10.92B	$10.32B
YoY Change	3.09%	-2.83%
Long-Term Investments	$34.78B	$33.34B	$33.34B
YoY Change	2.78%	-1.95%	-1.95%
Other Assets	$1.857B	$1.704B
YoY Change	3.0%	-0.87%
Total Long-Term Assets	$49.22B	$47.16B
YoY Change	5.64%	1.76%
TOTAL ASSETS
Total Short-Term Assets	$59.82B	$55.62B
Total Long-Term Assets	$49.22B	$47.16B
Total Assets	$109.0B	$102.8B	$102.8B
YoY Change	8.51%	5.45%	5.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.873B	$5.035B	$5.035B
YoY Change	-11.29%	1.31%	1.31%
Accrued Expenses	$905.0M	$932.0M	$932.0M
YoY Change	-3.21%	-6.52%	-6.52%
Deferred Revenue
YoY Change
Short-Term Debt	$265.0M	$265.0M	$265.0M
YoY Change	-3.64%	-3.64%	-3.64%
Long-Term Debt Due	$0.00	$1.500B	$1.500B
YoY Change	-100.0%	-6.19%	-6.19%
Total Short-Term Liabilities	$41.89B	$6.800B	$6.800B
YoY Change	5.43%	-80.51%	-13.28%
LONG-TERM LIABILITIES
Long-Term Debt	$25.20B	$22.35B	$22.35B
YoY Change	26.75%	5.63%	5.63%
Other Long-Term Liabilities	$1.650B	$11.25B	$11.25B
YoY Change	-1.73%	568.15%	31.75%
Total Long-Term Liabilities	$26.85B	$33.59B	$33.59B
YoY Change	24.53%	47.08%	13.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.89B	$6.800B	$6.800B
Total Long-Term Liabilities	$26.85B	$33.59B	$33.59B
Total Liabilities	$71.58B	$66.47B	$66.47B
YoY Change	11.05%	8.37%	8.25%
SHAREHOLDERS EQUITY
Retained Earnings	$30.71B	$29.72B
YoY Change	9.44%	9.73%
Common Stock	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.36B	$36.31B	$36.31B
YoY Change
Total Liabilities & Shareholders Equity	$109.0B	$102.8B	$102.8B
YoY Change	8.51%	5.45%	5.45%

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$1.989B	$949.0M	$6.025B
YoY Change	10.19%	-16.53%	-1.29%
Depreciation, Depletion And Amortization	$462.0M	$473.0M	$1.675B
YoY Change	29.05%	31.39%	1131.62%
Cash From Operating Activities	$6.469B	-$1.518B	$8.399B
YoY Change	154.58%	-190.79%	0.42%
INVESTING ACTIVITIES
Capital Expenditures	$301.0M	-$298.0M	-$1.152B
YoY Change	18.5%	-12.35%	-205.98%
Acquisitions	$1.638B		$649.0M
YoY Change	2585.25%		-81.33%
Other Investing Activities	$28.00M	$587.0M	-$3.408B
YoY Change	0.0%	-193.77%	-5509.52%
Cash From Investing Activities	-$3.184B	$289.0M	-$4.560B
YoY Change	101.77%	-129.92%	-52.69%
FINANCING ACTIVITIES
Cash Dividend Paid	$351.0M	$305.0M	$1.229B
YoY Change	13.59%	11.72%	11.32%
Common Stock Issuance & Retirement, Net			-$2.134B
YoY Change			-212.32%
Debt Paid & Issued, Net	$1.908B		$1.899B
YoY Change	13528.57%		77.81%
Cash From Financing Activities	-$531.0M	-258.0M	-1.318B
YoY Change	-264.91%	-80.38%	-411.58%
NET CHANGE
Cash From Operating Activities	$6.469B	-1.518B	8.399B
Cash From Investing Activities	-$3.184B	289.0M	-4.560B
Cash From Financing Activities	-$531.0M	-258.0M	-1.318B
Net Change In Cash	$2.755B	-1.487B	2.521B
YoY Change	115.07%	144.17%	-392.8%
FREE CASH FLOW
Cash From Operating Activities	$6.469B	-$1.518B	$8.399B
Capital Expenditures	$301.0M	-$298.0M	-$1.152B
Free Cash Flow	$6.168B	-$1.220B	$9.551B
YoY Change	169.7%	-160.64%	31.25%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2022	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2021	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2020	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2021	elv	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#ProfitLoss
CY2021	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#ProfitLoss
CY2020	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#ProfitLoss
CY2021	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2020	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-16751
CY2022	dei	Entity Registrant Name EntityRegistrantName	ELEVANCE HEALTH, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2145715
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	220 Virginia Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Indianapolis
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46204
CY2022	dei	City Area Code CityAreaCode	(833)
CY2022	dei	Local Phone Number LocalPhoneNumber	401-1577
CY2022	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01
CY2022	dei	Trading Symbol TradingSymbol	ELV
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	115691972993	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	237457776	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Indianapolis, Indiana
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7387000000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4880000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	28226000000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51122000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	789000000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	25641000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent	-9000000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent	-6000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	25952000000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	26267000000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	953000000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1881000000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	7083000000	usd
CY2021Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5681000000	usd
CY2022Q4	elv	Self Funded Receivables Net SelfFundedReceivablesNet	4663000000	usd
CY2021Q4	elv	Self Funded Receivables Net SelfFundedReceivablesNet	4010000000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	4298000000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	3749000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5281000000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4654000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	55617000000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	616000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	752000000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	632000000	usd
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	5685000000	usd
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	5225000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4316000000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3919000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	24383000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	24228000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10315000000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10615000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1704000000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1719000000	usd
CY2022Q4	us-gaap	Assets Assets	102772000000	usd
CY2021Q4	us-gaap	Assets Assets	97460000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	15596000000	usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	13518000000	usd
CY2022Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5933000000	usd
CY2021Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	5521000000	usd
CY2022Q4	us-gaap	Unearned Premiums UnearnedPremiums	1112000000	usd
CY2021Q4	us-gaap	Unearned Premiums UnearnedPremiums	1153000000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5607000000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4970000000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	265000000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	275000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1500000000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1599000000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9683000000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7849000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39696000000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34885000000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22349000000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21157000000	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	737000000	usd
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	802000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2034000000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2805000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1562000000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1683000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	66378000000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	61332000000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	237958067	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	237958067	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	241770746	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	241770746	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9084000000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9148000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	29724000000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	27088000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2503000000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-178000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36307000000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36060000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	87000000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	68000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36394000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36128000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102772000000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97460000000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	133229000000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	117373000000	usd
CY2020	us-gaap	Premiums Earned Net PremiumsEarnedNet	104109000000	usd
CY2022	elv	Product Revenue ProductRevenue	14978000000	usd
CY2021	elv	Product Revenue ProductRevenue	12657000000	usd
CY2020	elv	Product Revenue ProductRevenue	10384000000	usd
CY2022	us-gaap	Other Income OtherIncome	7453000000	usd
CY2021	us-gaap	Other Income OtherIncome	6913000000	usd
CY2020	us-gaap	Other Income OtherIncome	6315000000	usd
CY2022	elv	Operating Revenue OperatingRevenue	155660000000	usd
CY2021	elv	Operating Revenue OperatingRevenue	136943000000	usd
CY2020	elv	Operating Revenue OperatingRevenue	120808000000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	1485000000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1378000000	usd
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	usd
CY2022	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	-550000000	usd
CY2021	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	318000000	usd
CY2020	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	182000000	usd
CY2022	us-gaap	Revenues Revenues	156595000000	usd
CY2021	us-gaap	Revenues Revenues	138639000000	usd
CY2020	us-gaap	Revenues Revenues	121867000000	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	116487000000	usd
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	102645000000	usd
CY2020	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	88045000000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13035000000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10895000000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8953000000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17686000000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15914000000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17450000000	usd
CY2022	us-gaap	Interest Expense InterestExpense	851000000	usd
CY2021	us-gaap	Interest Expense InterestExpense	798000000	usd
CY2020	us-gaap	Interest Expense InterestExpense	784000000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	767000000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	441000000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21000000	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-36000000	usd
CY2022	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	148826000000	usd
CY2021	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	130714000000	usd
CY2020	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	115629000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7769000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7925000000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6238000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1750000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1830000000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1666000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	6019000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	6025000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6104000000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	4572000000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	25.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	25.04
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	18.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	24.81
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	24.73
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	17.98
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	5.12
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	4.52
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.80
CY2022	us-gaap	Profit Loss ProfitLoss	6019000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2260000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-457000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	428000000	usd
CY2022	elv	Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax	-3000000	usd
CY2021	elv	Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax	2000000	usd
CY2020	elv	Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	10000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	11000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	12000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	70000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-123000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	1000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2336000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-330000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	446000000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-11000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-2000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3700000000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5776000000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5018000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	6019000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	usd
CY2022	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	-550000000	usd
CY2021	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	318000000	usd
CY2020	elv	Net Gains Losses On Financial Instruments NetGainsLossesOnFinancialInstruments	182000000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	293000000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	562000000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	51000000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1675000000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1302000000	usd
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1154000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-76000000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	326000000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-540000000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	7000000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	73000000	usd
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	198000000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	264000000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	255000000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	283000000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2510000000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2138000000	usd
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	256000000	usd
CY2022	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	-11000000	usd
CY2021	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	70000000	usd
CY2020	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	32000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-120000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-37000000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	283000000	usd
CY2022	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	2254000000	usd
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	2597000000	usd
CY2020	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	3528000000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-42000000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-113000000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	202000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	824000000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	719000000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1978000000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-338000000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	140000000	usd
CY2020	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	72000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	66000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-21000000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-45000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8399000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8364000000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10688000000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24946000000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18669000000	usd
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19492000000	usd
CY2022	elv	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	11988000000	usd
CY2021	elv	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	10269000000	usd
CY2020	elv	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	11318000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	10620000000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4344000000	usd
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4741000000	usd
CY2022	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	301000000	usd
CY2021	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	956000000	usd
CY2020	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	849000000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	649000000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3476000000	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1976000000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1152000000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1087000000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1021000000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	120000000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	63000000	usd
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	45000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4560000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9638000000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7324000000	usd
CY2022	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-300000000	usd
CY2021	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	50000000	usd
CY2020	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-150000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3071000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3462000000	usd
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2484000000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1899000000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1068000000	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1932000000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1365000000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1325000000	usd
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	970000000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1375000000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1050000000	usd
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1670000000	usd
CY2022	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	302000000	usd
CY2021	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	956000000	usd
CY2020	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	849000000	usd
CY2022	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	933000000	usd
CY2021	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-376000000	usd
CY2020	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	486000000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2316000000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1900000000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2700000000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	1229000000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	1104000000	usd
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	954000000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	182000000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	203000000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	176000000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	93000000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	102000000	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	128000000	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	41000000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	27000000	usd
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1318000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	423000000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2567000000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14000000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7000000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2507000000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-861000000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	804000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4880000000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5741000000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4937000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7387000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4880000000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5741000000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31693000000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	4572000000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	446000000	usd
CY2020	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2700000000	usd
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	961000000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-181000000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33199000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	6095000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-330000000	usd
CY2021	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	79000000	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	1900000000	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	1111000000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	355000000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-259000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36128000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	6019000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2336000000	usd
CY2022	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	36000000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2316000000	usd
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	1234000000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	352000000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-232000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36394000000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Organization <div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December 31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (“CarelonRx”) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Carelon — this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes made to our segments in 2022 associated with this branding strategy. Through December 31, 2022, we managed our operations by customer types through four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. Our branding strategy reflects the evolution of </span></div>our business from a traditional health insurance company into a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our business in the future. For additional discussion, including the changes to our reportable segments for 2023, see Note 20, “Segment Information.”
CY2022Q4	elv	Number Of Medical Members Served NumberOfMedicalMembersServed	47500000	individuals
CY2022Q4	elv	Number Of Counties In Geographical Region Not Served NumberOfCountiesInGeographicalRegionNotServed	30	counties
CY2022Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior year amounts have been reclassified to conform to the current year presentation.</span>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.</span>
CY2022Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	258000000	usd
CY2021Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	173000000	usd
CY2022	elv	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2022Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	152000000	usd
CY2021Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	142000000	usd
CY2022Q4	elv	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	68000000	usd
CY2021Q4	elv	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	50000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	744000000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	648000000	usd
CY2022	us-gaap	Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses	We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	34000000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.90
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	511000000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	588000000	usd
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	558000000	usd
CY2021Q4	elv	Patient Protection Affordable Care Act Health Insurance Provider Fee PatientProtectionAffordableCareActHealthInsuranceProviderFee	15523000000	usd
CY2021	elv	Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid	1570000000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	136000000	usd
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	258000000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	170000000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	808000000	usd
CY2022Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets	240000000	usd
CY2021Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets	295000000	usd
CY2022Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets	109000000	usd
CY2021Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets	102000000	usd
CY2022Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities	185000000	usd
CY2021Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities	571000000	usd
CY2022Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities	20000000	usd
CY2021Q4	elv	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities	179000000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	15000000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	6000000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	32000000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	556000000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	267000000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-107000000	usd
CY2022Q4	elv	Total Intangible Assets Acquired TotalIntangibleAssetsAcquired	339000000	usd
CY2021Q4	elv	Total Intangible Assets Acquired TotalIntangibleAssetsAcquired	1597000000	usd
CY2022	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	39000000	usd
CY2021	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	202000000	usd
CY2020	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	653000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	9000000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	6000000	usd
CY2022Q4	elv	Equity Securities EquitySecurities	953000000	usd
CY2021Q4	elv	Equity Securities EquitySecurities	1881000000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	1528000000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	1419000000	usd
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	915000000	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	43000000	usd
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	41000000	usd
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	38000000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	1485000000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1378000000	usd
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	877000000	usd
CY2022	elv	Investment Gains Losses InvestmentGainsLosses	-630000000	usd
CY2021	elv	Investment Gains Losses InvestmentGainsLosses	311000000	usd
CY2020	elv	Investment Gains Losses InvestmentGainsLosses	184000000	usd
CY2022Q4	elv	Number Of Fixed Maturity Investments That Did Not Produce Income NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome	8
CY2021Q4	elv	Number Of Fixed Maturity Investments That Did Not Produce Income NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome	2
CY2022Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	752000000	usd
CY2021Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	632000000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	245000000	usd
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	205000000	usd
CY2022Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	2457000000	usd
CY2021Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	2155000000	usd
CY2022	elv	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2022Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	57000000	usd
CY2021Q4	us-gaap	Derivative Asset Collateral Obligation To Return Cash Offset DerivativeAssetCollateralObligationToReturnCashOffset	18000000	usd
CY2022Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	1525000000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	33000000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	71000000	usd
CY2022Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	12000000	usd
CY2022Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	12000000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	21000000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	59000000	usd
CY2021Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	1407000000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	47000000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	29000000	usd
CY2021Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	21000000	usd
CY2021Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	21000000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral	26000000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	8000000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	80000000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7000000	usd
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3567000000	usd
CY2022Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	2457000000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33787000000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	60000000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2415000000	usd
CY2021Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	2155000000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	33507000000	usd
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1000000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	449000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-17000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	443000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	242000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	41000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	9000000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	19000000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	581000000	usd
CY2022	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	392000000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	19000000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	3000000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	216000000	usd

CY2022

dei

Amendment Flag

AmendmentFlag

false

CY2022

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2022

CY2022

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2022

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2022

us-gaap

Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration

RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2021

us-gaap

Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration

RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2020

us-gaap

Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration

RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2021

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2022

us-gaap

Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List

FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2022#ProfitLoss

CY2021

us-gaap

Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List

FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2022#ProfitLoss

CY2020

us-gaap

Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List

FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList

http://fasb.org/us-gaap/2022#ProfitLoss

CY2021

us-gaap

Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List

DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2022

us-gaap

Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List

DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2020

us-gaap

Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List

DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList

http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense

CY2021Q4

us-gaap

Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List

OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent

CY2022Q4

us-gaap

Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List

OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent

CY2022Q4

us-gaap

Operating Lease Liability Current Statement Of Financial Position Extensible List

OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent

CY2021Q4

us-gaap

Operating Lease Liability Current Statement Of Financial Position Extensible List

OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent

CY2021Q4

us-gaap

Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List

OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List

OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList

http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent

CY2022

dei

Document Type

DocumentType

10-K

CY2022

dei

Document Annual Report

DocumentAnnualReport

true

CY2022

dei

Document Period End Date

DocumentPeriodEndDate

2022-12-31

CY2022

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2022

dei

Document Transition Report

DocumentTransitionReport

false

CY2022

dei

Entity File Number

EntityFileNumber

001-16751

CY2022

dei

Entity Registrant Name

EntityRegistrantName

ELEVANCE HEALTH, INC.

CY2022

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

IN

CY2022

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

35-2145715

CY2022

dei

Entity Address Address Line1

EntityAddressAddressLine1

220 Virginia Avenue

CY2022

dei

Entity Address City Or Town

EntityAddressCityOrTown

Indianapolis

CY2022

dei

Entity Address State Or Province

EntityAddressStateOrProvince

IN

CY2022

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

46204

CY2022

dei

City Area Code

CityAreaCode

(833)

CY2022

dei

Local Phone Number

LocalPhoneNumber

401-1577

CY2022

dei

Security12b Title

Security12bTitle

Common Stock, Par Value $0.01

CY2022

dei

Trading Symbol

TradingSymbol

ELV

CY2022

dei

Security Exchange Name

SecurityExchangeName

NYSE

CY2022

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2022

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2022

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2022

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2022

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2022

dei

Entity Small Business

EntitySmallBusiness

false

CY2022

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2022

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2022

dei

Entity Shell Company

EntityShellCompany

false

CY2022Q2

dei

Entity Public Float

EntityPublicFloat

115691972993

usd

CY2023Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

237457776

shares

CY2022

dei

Auditor Firm

AuditorFirmId

42

CY2022

dei

Auditor Name

AuditorName

Ernst & Young LLP

CY2022

dei

Auditor Location

AuditorLocation

Indianapolis, Indiana

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

7387000000

usd

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4880000000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

28226000000

usd

CY2021Q4

us-gaap

Assets Current

AssetsCurrent

51122000000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

789000000

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Current

DebtSecuritiesAvailableForSaleAmortizedCostCurrent

25641000000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Current

DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent

-9000000

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Current

DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent

-6000000

usd

CY2022Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

25952000000

usd

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

26267000000

usd

CY2022Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

953000000

usd

CY2021Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1881000000

usd

CY2022Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

7083000000

usd

CY2021Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5681000000

usd

CY2022Q4

elv

Self Funded Receivables Net

SelfFundedReceivablesNet

4663000000

usd

CY2021Q4

elv

Self Funded Receivables Net

SelfFundedReceivablesNet

4010000000

usd

CY2022Q4

us-gaap

Other Receivables

OtherReceivables

4298000000

usd

CY2021Q4

us-gaap

Other Receivables

OtherReceivables

3749000000

usd

CY2022Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

5281000000

usd

CY2021Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

4654000000

usd

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

55617000000

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Amortized Cost Noncurrent

DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent

616000000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Noncurrent

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent

0

usd

CY2022Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

752000000

usd

CY2021Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

632000000

usd

CY2022Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

5685000000

usd

CY2021Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

5225000000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4316000000

usd

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3919000000

usd

CY2022Q4

us-gaap

Goodwill

24383000000

usd

CY2021Q4

us-gaap

Goodwill

24228000000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10315000000

usd

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10615000000

usd

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1704000000

usd

CY2021Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1719000000

usd

CY2022Q4

us-gaap

Assets

102772000000

usd

CY2021Q4

us-gaap

Assets

97460000000

usd

CY2022Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15596000000

usd

CY2021Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

13518000000

usd

CY2022Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

5933000000

usd

CY2021Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

5521000000

usd

CY2022Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1112000000

usd

CY2021Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1153000000

usd

CY2022Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5607000000

usd

CY2021Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4970000000

usd

CY2022Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

265000000

usd

CY2021Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

275000000

usd

CY2022Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1500000000

usd

CY2021Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1599000000

usd

CY2022Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

9683000000

usd

CY2021Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

7849000000

usd

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

39696000000

usd

CY2021Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

34885000000

usd

CY2022Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

22349000000

usd

CY2021Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

21157000000

usd

CY2022Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

737000000

usd

CY2021Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

802000000

usd

CY2022Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2034000000

usd

CY2021Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2805000000

usd

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1562000000

usd

CY2021Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1683000000

usd

CY2022Q4

us-gaap

Liabilities

66378000000

usd

CY2021Q4

us-gaap

Liabilities

61332000000

usd

CY2022Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2021Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2022Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2021Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

usd

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

237958067

shares

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

237958067

shares

CY2021Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

241770746

shares

CY2021Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

241770746

shares

CY2022Q4

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2021Q4

us-gaap

Common Stock Value

CommonStockValue

2000000

usd

CY2022Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9084000000

usd

CY2021Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9148000000

usd

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

29724000000

usd

CY2021Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

27088000000

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-2503000000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-178000000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

36307000000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

36060000000

usd

CY2022Q4

us-gaap

Minority Interest

MinorityInterest

87000000

usd

CY2021Q4

us-gaap

Minority Interest

MinorityInterest

68000000

usd

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36394000000

usd

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36128000000

usd

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

102772000000

usd

CY2021Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

97460000000

usd

CY2022

us-gaap

Premiums Earned Net

PremiumsEarnedNet

133229000000

usd

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

usd

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

usd

CY2022

elv

Product Revenue

ProductRevenue

14978000000

usd

CY2021

elv

Product Revenue

ProductRevenue

12657000000

usd

CY2020

elv

Product Revenue

ProductRevenue

10384000000

usd

CY2022

us-gaap

Other Income

OtherIncome

7453000000

usd

CY2021

us-gaap

Other Income

OtherIncome

6913000000

usd

CY2020

us-gaap

Other Income

OtherIncome

6315000000

usd

CY2022

elv

Operating Revenue

OperatingRevenue

155660000000

usd

CY2021

elv

Operating Revenue

OperatingRevenue

136943000000

usd

CY2020

elv

Operating Revenue

OperatingRevenue

120808000000

usd

CY2022

us-gaap

Net Investment Income

NetInvestmentIncome

1485000000

usd

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

usd

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

usd

CY2022

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

-550000000

usd

CY2021

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

usd

CY2020

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

usd

CY2022

us-gaap

Revenues

156595000000

usd

CY2021

us-gaap

Revenues

138639000000

usd

CY2020

us-gaap

Revenues

121867000000

usd

CY2022

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

116487000000

usd

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

usd

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

usd

CY2022

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

13035000000

usd

CY2021

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

10895000000

usd

CY2020

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

8953000000

usd

CY2022

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

17686000000

usd

CY2021

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

15914000000

usd

CY2020

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

17450000000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

851000000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

798000000

usd

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

usd

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

767000000

usd

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

441000000

usd

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

usd

CY2022

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

usd

CY2021

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-21000000

usd

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

usd

CY2022

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

148826000000

usd

CY2021

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

130714000000

usd

CY2020

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

115629000000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7769000000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7925000000

usd

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

6238000000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1750000000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

usd

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

usd

CY2022

us-gaap

Profit Loss

ProfitLoss

6019000000

usd

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

usd

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

usd

CY2022

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-6000000

usd

CY2021

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-9000000

usd

CY2020

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

usd

CY2022

us-gaap

Net Income Loss

NetIncomeLoss

6025000000

usd

CY2021

us-gaap

Net Income Loss

NetIncomeLoss

6104000000

usd

CY2020

us-gaap

Net Income Loss

NetIncomeLoss

4572000000

usd

CY2022

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

25.10

CY2021

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

25.04

CY2020

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

18.23

CY2022

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

24.81

CY2021

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

24.73

CY2020

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

17.98

CY2022

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

5.12

CY2021

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

4.52

CY2020

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.80

CY2022

us-gaap

Profit Loss

ProfitLoss

6019000000

usd

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

usd

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-2260000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-457000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

428000000

usd

CY2022

elv

Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax

ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax

-3000000

usd

CY2021

elv

Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax

ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax

2000000

usd

CY2020

elv

Change In Non Credit Component Of Impairment Losses On Investments Net Of Tax

ChangeInNonCreditComponentOfImpairmentLossesOnInvestmentsNetOfTax

0

usd

CY2022

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

10000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

11000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

12000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

70000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-123000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

1000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-13000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

-9000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

7000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-2336000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

usd

CY2022

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-6000000

usd

CY2021

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

-9000000

usd

CY2020

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

0

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-11000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-2000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2022

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3700000000

usd

CY2021

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5776000000

usd

CY2020

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

5018000000

usd

CY2022

us-gaap

Profit Loss

ProfitLoss

6019000000

usd

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

usd

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

usd

CY2022

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

-550000000

usd

CY2021

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

usd

CY2020

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

usd

CY2022

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

293000000

usd

CY2021

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

562000000

usd

CY2020

us-gaap

Income Loss From Equity Method Investments

IncomeLossFromEquityMethodInvestments

51000000

usd

CY2022

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1675000000

usd

CY2021

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1302000000

usd

CY2020

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

1154000000

usd

CY2022

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-76000000

usd

CY2021

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

326000000

usd

CY2020

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-540000000

usd

CY2022

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

7000000

usd

CY2021

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

73000000

usd

CY2020

us-gaap

Impairment Of Long Lived Assets Held For Use

ImpairmentOfLongLivedAssetsHeldForUse

198000000

usd

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

264000000

usd

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

255000000

usd

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

usd

CY2022

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

2510000000

usd

CY2021

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

2138000000

usd

CY2020

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

256000000

usd

CY2022

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

-11000000

usd

CY2021

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

70000000

usd

CY2020

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

32000000

usd

CY2022

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

-120000000

usd

CY2021

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

-37000000

usd

CY2020

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

283000000

usd

CY2022

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

2254000000

usd

CY2021

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

2597000000

usd

CY2020

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

3528000000

usd

CY2022

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-42000000

usd

CY2021

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-113000000

usd

CY2020

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

202000000

usd

CY2022

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

824000000

usd

CY2021

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

719000000

usd

CY2020

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

1978000000

usd

CY2022

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-338000000

usd

CY2021

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

140000000

usd

CY2020

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

72000000

usd

CY2022

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

66000000

usd

CY2021

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-21000000

usd

CY2020

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-45000000

usd

CY2022

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8399000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8364000000

usd

CY2020

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

10688000000

usd

CY2022

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

24946000000

usd

CY2021

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

18669000000

usd

CY2020

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

19492000000

usd

CY2022

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

11988000000

usd

CY2021

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

10269000000

usd

CY2020

elv

Proceedsfromsaleofequityandfixedmaturitysecurities

11318000000

usd

CY2022

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

10620000000

usd

CY2021

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

4344000000

usd

CY2020

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

4741000000

usd

CY2022

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

301000000

usd

CY2021

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

956000000

usd

CY2020

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

849000000

usd

CY2022

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

649000000

usd

CY2021

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

3476000000

usd

CY2020

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1976000000

usd

CY2022

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1152000000

usd

CY2021

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1087000000

usd

CY2020

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

1021000000

usd

CY2022

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

120000000

usd

CY2021

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

63000000

usd

CY2020

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

45000000

usd

CY2022

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-4560000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-9638000000

usd

CY2020

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-7324000000

usd

CY2022

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-300000000

usd

CY2021

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

50000000

usd

CY2020

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-150000000

usd

CY2022

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

3071000000

usd

CY2021

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

3462000000

usd

CY2020

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2484000000

usd

CY2022

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1899000000

usd

CY2021

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1068000000

usd

CY2020

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

1932000000

usd

CY2022

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

1365000000

usd

CY2021

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

1325000000

usd

CY2020

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

970000000

usd

CY2022

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1375000000

usd

CY2021

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1050000000

usd

CY2020

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1670000000

usd

CY2022

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

302000000

usd

CY2021

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

956000000

usd

CY2020

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

849000000

usd

CY2022

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

933000000

usd

CY2021

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-376000000

usd

CY2020

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

486000000

usd

CY2022

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

2316000000

usd

CY2021

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1900000000

usd

CY2020

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

2700000000

usd

CY2022

us-gaap

Payments Of Dividends

PaymentsOfDividends

1229000000

usd

CY2021

us-gaap

Payments Of Dividends

PaymentsOfDividends

1104000000

usd

CY2020

us-gaap

Payments Of Dividends

PaymentsOfDividends

954000000

usd

CY2022

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

182000000

usd

CY2021

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

203000000

usd

CY2020

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

176000000

usd

CY2022

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

93000000

usd

CY2021

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

102000000

usd

CY2020

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

128000000

usd

CY2022

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

41000000

usd

CY2021

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

27000000

usd

CY2020

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

2000000

usd

CY2022

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1318000000

usd

CY2021

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

423000000

usd

CY2020

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-2567000000

usd

CY2022

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-14000000

usd

CY2021

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

-10000000

usd

CY2020

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

7000000

usd

CY2022

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

2507000000

usd

CY2021

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-861000000

usd

CY2020

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

804000000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

4880000000

usd

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

5741000000

usd

CY2019Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

4937000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

7387000000

usd

CY2021Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

4880000000

usd

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

5741000000

usd

CY2019Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

31693000000

usd

CY2020

us-gaap

Profit Loss

ProfitLoss

4572000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

usd

CY2020

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2700000000

usd

CY2020

us-gaap

Dividends Common Stock

DividendsCommonStock

961000000

usd

CY2020

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

330000000

usd

CY2020

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-181000000

usd

CY2020Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

33199000000

usd

CY2021

us-gaap

Profit Loss

ProfitLoss

6095000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

usd

CY2021

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

79000000

usd

CY2021

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1900000000

usd

CY2021

us-gaap

Dividends Common Stock

DividendsCommonStock

1111000000

usd

CY2021

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

355000000

usd

CY2021

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-259000000

usd

CY2021Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36128000000

usd

CY2022

us-gaap

Profit Loss

ProfitLoss

6019000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-2336000000

usd

CY2022

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

36000000

usd

CY2022

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2316000000

usd

CY2022

us-gaap

Dividends Common Stock

DividendsCommonStock

1234000000

usd

CY2022

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

352000000

usd

CY2022

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-232000000

usd

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

36394000000

usd

CY2022

us-gaap

Nature Of Operations

NatureOfOperations

Organization <div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.</div><div style="margin-bottom:9pt;text-indent:18pt">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47.5 million medical members through our affiliated health plans as of December 31, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also unaffiliated health plans, including pharmacy benefit management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.</div><div style="margin-bottom:9pt;text-indent:18pt">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum Healthcare, Simply Healthcare, UniCare and/or Wellpoint. We offer PBM services through our CarelonRx, Inc. (“CarelonRx”) subsidiary, which was named IngenioRx, Inc. prior to January 1, 2023. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.</div><div style="margin-bottom:6pt;text-indent:18pt">As part of our name change to Elevance Health, in June 2022, we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">•Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt">•Carelon — this brand brings together our healthcare-related services and capabilities, including our formerly named Diversified Business Group and IngenioRx businesses, under a single brand name.</div><div style="margin-bottom:12pt;text-indent:18pt">There were no changes made to our segments in 2022 associated with this branding strategy. Through December 31, 2022, we managed our operations by customer types through four reportable segments: Commercial & Specialty Business, Government Business, CarelonRx (formerly known as IngenioRx) and Other. Our branding strategy reflects the evolution of </div>our business from a traditional health insurance company into a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our business in the future. For additional discussion, including the changes to our reportable segments for 2023, see Note 20, “Segment Information.”

CY2022Q4

elv

Number Of Medical Members Served

NumberOfMedicalMembersServed

47500000

individuals

CY2022Q4

elv

Number Of Counties In Geographical Region Not Served

NumberOfCountiesInGeographicalRegionNotServed

30

counties

CY2022Q4

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2022

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.

CY2022

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical claims payable. Actual results could differ from those estimates.

CY2022Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

258000000

usd

CY2021Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

173000000

usd

CY2022

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2022Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

152000000

usd

CY2021Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

142000000

usd

CY2022Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

68000000

usd

CY2021Q4

elv

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

50000000

usd

CY2022Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

744000000

usd

CY2021Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

648000000

usd

CY2022

us-gaap

Defined Benefit Plan Alternative Method Used To Amortize Net Gains And Losses

DefinedBenefitPlanAlternativeMethodUsedToAmortizeNetGainsAndLosses

We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of net periodic benefit cost.

CY2022

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

34000000

usd

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent

SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

0.90

CY2022

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

511000000

usd

CY2021

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

588000000

usd

CY2020

us-gaap

Marketing And Advertising Expense

MarketingAndAdvertisingExpense

558000000

usd

CY2021Q4

elv

Patient Protection Affordable Care Act Health Insurance Provider Fee

PatientProtectionAffordableCareActHealthInsuranceProviderFee

15523000000

usd

CY2021

elv

Patient Protection Affordable Care Act Health Insurance Provider Fee Amount Paid

PatientProtectionAffordableCareActHealthInsuranceProviderFeeAmountPaid

1570000000

usd

CY2021

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

136000000

usd

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

170000000

usd

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

808000000

usd

CY2022Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets

240000000

usd

CY2021Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Accounts Receivables And Other Current Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAccountsReceivablesAndOtherCurrentAssets

295000000

usd

CY2022Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets

109000000

usd

CY2021Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property And Equipment And Other Long Term Assets

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyAndEquipmentAndOtherLongTermAssets

102000000

usd

CY2022Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities

185000000

usd

CY2021Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Claims And Other Policyholder Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalClaimsAndOtherPolicyholderLiabilities

571000000

usd

CY2022Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

20000000

usd

CY2021Q4

elv

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Other Current Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

179000000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

15000000

usd

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

6000000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities

32000000

usd

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities

556000000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

267000000

usd

CY2021Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

-107000000

usd

CY2022Q4

elv

Total Intangible Assets Acquired

TotalIntangibleAssetsAcquired

339000000

usd

CY2021Q4

elv

Total Intangible Assets Acquired

TotalIntangibleAssetsAcquired

1597000000

usd

CY2022

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

39000000

usd

CY2021

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

202000000

usd

CY2020

us-gaap

Restructuring And Related Cost Incurred Cost

RestructuringAndRelatedCostIncurredCost

653000000

usd

CY2022Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

9000000

usd

CY2021Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

6000000

usd

CY2022Q4

elv

Equity Securities

EquitySecurities

953000000

usd

CY2021Q4

elv

Equity Securities

EquitySecurities

1881000000

usd

CY2022

us-gaap

Investment Income Net

InvestmentIncomeNet

1528000000

usd

CY2021

us-gaap

Investment Income Net

InvestmentIncomeNet

1419000000

usd

CY2020

us-gaap

Investment Income Net

InvestmentIncomeNet

915000000

usd

CY2022

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

43000000

usd

CY2021

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

41000000

usd

CY2020

us-gaap

Investment Income Investment Expense

InvestmentIncomeInvestmentExpense

38000000

usd

CY2022

us-gaap

Net Investment Income

NetInvestmentIncome

1485000000

usd

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

usd

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

usd

CY2022

elv

Investment Gains Losses

InvestmentGainsLosses

-630000000

usd

CY2021

elv

Investment Gains Losses

InvestmentGainsLosses

311000000

usd

CY2020

elv

Investment Gains Losses

InvestmentGainsLosses

184000000

usd

CY2022Q4

elv

Number Of Fixed Maturity Investments That Did Not Produce Income

NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome

8

CY2021Q4

elv

Number Of Fixed Maturity Investments That Did Not Produce Income

NumberOfFixedMaturityInvestmentsThatDidNotProduceIncome

2

CY2022Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

752000000

usd

CY2021Q4

us-gaap

Assets Held By Insurance Regulators

AssetsHeldByInsuranceRegulators

632000000

usd

CY2022Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

245000000

usd

CY2021Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

205000000

usd

CY2022Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2457000000

usd

CY2021Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

2155000000

usd

CY2022

elv

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2022Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

57000000

usd

CY2021Q4

us-gaap

Derivative Asset Collateral Obligation To Return Cash Offset

DerivativeAssetCollateralObligationToReturnCashOffset

18000000

usd

CY2022Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1525000000

usd

CY2022Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

33000000

usd

CY2022Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

71000000

usd

CY2022Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

12000000

usd

CY2022Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

12000000

usd

CY2022Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

21000000

usd

CY2022Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

59000000

usd

CY2021Q4

us-gaap

Derivative Notional Amount

DerivativeNotionalAmount

1407000000

usd

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Asset

DerivativeFairValueOfDerivativeAsset

47000000

usd

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Liability

DerivativeFairValueOfDerivativeLiability

29000000

usd

CY2021Q4

us-gaap

Derivative Asset Fair Value Gross Liability

DerivativeAssetFairValueGrossLiability

21000000

usd

CY2021Q4

us-gaap

Derivative Liability Fair Value Gross Asset

DerivativeLiabilityFairValueGrossAsset

21000000

usd

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Asset Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

26000000

usd

CY2021Q4

us-gaap

Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral

DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

8000000

usd

CY2022

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

80000000

usd

CY2021

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

7000000

usd

CY2020

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-2000000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

3567000000

usd

CY2022Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2457000000

usd

CY2022Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

33787000000

usd

CY2022Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

60000000

usd

CY2021Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2415000000

usd

CY2021Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

2155000000

usd

CY2021Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

33507000000

usd

CY2021Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

1000000

usd

CY2021Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

449000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-1000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-17000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

443000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

242000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

41000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

9000000

usd

CY2022

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

19000000

usd

CY2022Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

581000000

usd

CY2022

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

0

usd

CY2020Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

392000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

19000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

216000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

22000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

157000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

3000000

usd

CY2021

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

5000000

usd

CY2021Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

449000000

usd

CY2021

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

18000000

usd

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-22000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-5000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

101000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

41000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

46000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

10000000

usd

CY2020

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

2000000

usd

CY2020Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

392000000

usd

CY2020

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-19000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Investments

DeferredTaxAssetsInvestments

340000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

379000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

511000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

301000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

246000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

147000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves

156000000

usd

CY2022Q4

elv

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

200000000

usd

CY2021Q4

elv

Deferred Tax Assets Leasing Arrangements

DeferredTaxAssetsLeasingArrangements

216000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

173000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits

170000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

34000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

35000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

208000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

201000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Investments

DeferredTaxAssetsInvestments

0

usd

CY2022Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

267000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Other

DeferredTaxAssetsOther

207000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

2049000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Gross

DeferredTaxAssetsGross

1742000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

203000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

212000000

usd

CY2022Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1846000000

usd

CY2021Q4

us-gaap

Deferred Tax Assets Net

DeferredTaxAssetsNet

1530000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

2059000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets

DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

2071000000

usd

CY2022Q4

elv

Deferred Tax Liabilities Non Us Intangible Assets

DeferredTaxLiabilitiesNonUSIntangibleAssets

380000000

usd

CY2021Q4

elv

Deferred Tax Liabilities Non Us Intangible Assets

DeferredTaxLiabilitiesNonUSIntangibleAssets

452000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Capitalized Software

DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware

601000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Deferred Expense Capitalized Software

DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware

777000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

62000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

45000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Investments

DeferredTaxLiabilitiesInvestments

0

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Investments

DeferredTaxLiabilitiesInvestments

295000000

usd

CY2022Q4

elv

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

317000000

usd

CY2021Q4

elv

Deferred Taxliabilities Deferred Expense Retirementbenefits

DeferredTaxliabilitiesDeferredExpenseRetirementbenefits

314000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

123000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Leasing Arrangements

DeferredTaxLiabilitiesLeasingArrangements

126000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

201000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities Prepaid Expenses

DeferredTaxLiabilitiesPrepaidExpenses

152000000

usd

CY2022Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

3743000000

usd

CY2021Q4

us-gaap

Deferred Income Tax Liabilities

DeferredIncomeTaxLiabilities

4232000000

usd

CY2022Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

1897000000

usd

CY2021Q4

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

2702000000

usd

CY2022

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1469000000

usd

CY2021

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1467000000

usd

CY2020

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

1724000000

usd

CY2022

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

98000000

usd

CY2021

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

18000000

usd

CY2020

us-gaap

Current Foreign Tax Expense Benefit

CurrentForeignTaxExpenseBenefit

7000000

usd

CY2022

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

179000000

usd

CY2021

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

165000000

usd

CY2020

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

461000000

usd

CY2022

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1746000000

usd

CY2021

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

1650000000

usd

CY2020

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2192000000

usd

CY2022

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

4000000

usd

CY2021

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

180000000

usd

CY2020

us-gaap

Deferred Other Tax Expense Benefit

DeferredOtherTaxExpenseBenefit

-526000000

usd

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1750000000

usd

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

usd

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

usd

CY2022

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1631000000

usd

CY2022

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2021

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1664000000

usd

CY2021

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2020

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

1310000000

usd

CY2020

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.210

CY2022

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

238000000

usd

CY2022

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.030

CY2021

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

258000000

usd

CY2021

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.033

CY2020

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

235000000

usd

CY2020

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

0.038

CY2022

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

19000000

usd

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.002

CY2021

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

22000000

usd

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.003

CY2020

us-gaap

Income Tax Reconciliation Deductions

IncomeTaxReconciliationDeductions

22000000

usd

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Deductions

EffectiveIncomeTaxRateReconciliationDeductions

0.004

CY2022

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

usd

CY2022

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2021

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

0

usd

CY2021

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0

CY2020

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFee

330000000

usd

CY2020

elv

Effective Income Tax Reconciliation Patient Protection Affordable Care Act Health Insurance Provider Fee Percent

EffectiveIncomeTaxReconciliationPatientProtectionAffordableCareActHealthInsuranceProviderFeePercent

0.053

CY2022

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

0

usd

CY2022

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

0

CY2021

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

0

usd

CY2021

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

0

CY2020

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Amount

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsAmount

-110000000

usd

CY2020

elv

Effective Income Tax Rate Reconciliation Recent Acquisitions Percent

EffectiveIncomeTaxRateReconciliationRecentAcquisitionsPercent

-0.018

CY2021

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.009

CY2022

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-100000000

usd

CY2020

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-77000000

usd

CY2022

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.013

CY2021

us-gaap

Income Tax Reconciliation Other Adjustments

IncomeTaxReconciliationOtherAdjustments

-70000000

usd

CY2020

us-gaap

Effective Income Tax Rate Reconciliation Other Adjustments

EffectiveIncomeTaxRateReconciliationOtherAdjustments

-0.012

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1750000000

usd

CY2022

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.225

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

usd

CY2021

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.231

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

usd

CY2020

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.267

CY2022

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1750000000

usd

CY2022

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

7.21

CY2021

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1830000000

usd

CY2021

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

7.41

CY2020

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1666000000

usd

CY2020

us-gaap

Unusual Or Infrequent Item Earnings Per Share Impact Net

UnusualOrInfrequentItemEarningsPerShareImpactNet

6.55

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

271000000

usd

CY2020Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

249000000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

22000000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

10000000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

57000000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

17000000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

1000000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions

UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

5000000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

349000000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits

UnrecognizedTaxBenefits

271000000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

328000000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits That Would Impact Effective Tax Rate

UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

250000000

usd

CY2022Q4

elv

Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate In Future Periods If Recognized

UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRateInFuturePeriodsIfRecognized

2000000

usd

CY2022

elv

Income Tax Refund Claims Filed

IncomeTaxRefundClaimsFiled

92000000

usd

CY2017

elv

Income Tax Refund Claims Filed

IncomeTaxRefundClaimsFiled

310000000

usd

CY2022

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-13000000

usd

CY2021

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-9000000

usd

CY2020

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Expense

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

-7000000

usd

CY2022Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

55000000

usd

CY2021Q4

us-gaap

Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued

UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

42000000

usd

CY2022Q4

us-gaap

Income Tax Receivable

IncomeTaxReceivable

440000000

usd

CY2021Q4

us-gaap

Income Tax Receivable

IncomeTaxReceivable

173000000

usd

CY2022

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1594000000

usd

CY2021

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1299000000

usd

CY2020

us-gaap

Income Taxes Paid

IncomeTaxesPaid

1790000000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

7119000000

usd

CY2021Q4

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

8259000000

usd

CY2022Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

2803000000

usd

CY2021Q4

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

4340000000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

4316000000

usd

CY2021Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3919000000

usd

CY2022

us-gaap

Depreciation

123000000

usd

CY2021

us-gaap

Depreciation

136000000

usd

CY2020

us-gaap

Depreciation

176000000

usd

CY2022

elv

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

661000000

usd

CY2021

elv

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

532000000

usd

CY2020

elv

Amortization Expense On Software And Leasehold Improvements

AmortizationExpenseOnSoftwareAndLeaseholdImprovements

462000000

usd

CY2022

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

599000000

usd

CY2021

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

485000000

usd

CY2020

us-gaap

Capitalized Computer Software Amortization1

CapitalizedComputerSoftwareAmortization1

412000000

usd

CY2022Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

5354000000

usd

CY2021Q4

us-gaap

Capitalized Computer Software Gross

CapitalizedComputerSoftwareGross

5626000000

usd

CY2022

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

7000000

usd

CY2021

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

73000000

usd

CY2020

us-gaap

Impairment Of Long Lived Assets To Be Disposed Of

ImpairmentOfLongLivedAssetsToBeDisposedOf

198000000

usd

CY2020Q4

us-gaap

Goodwill

21691000000

usd

CY2021

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

2537000000

usd

CY2021Q4

us-gaap

Goodwill

24228000000

usd

CY2022

us-gaap

Goodwill Period Increase Decrease

GoodwillPeriodIncreaseDecrease

155000000

usd

CY2022Q4

us-gaap

Goodwill

24383000000

usd

CY2022Q4

us-gaap

Goodwill Impaired Accumulated Impairment Loss

GoodwillImpairedAccumulatedImpairmentLoss

0

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

7127000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

4279000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

2848000000

usd

CY2021Q4

us-gaap

Finite Lived Intangible Assets Gross

FiniteLivedIntangibleAssetsGross

6532000000

usd

CY2021Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

3506000000

usd

CY2021Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

3026000000

usd

CY2022Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7467000000

usd

CY2022Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7467000000

usd

CY2021Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7589000000

usd

CY2021Q4

us-gaap

Indefinite Lived Intangible Assets Excluding Goodwill

IndefiniteLivedIntangibleAssetsExcludingGoodwill

7589000000

usd

CY2022Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

14594000000

usd

CY2022Q4

elv

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

4279000000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10315000000

usd

CY2021Q4

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

14121000000

usd

CY2021Q4

elv

Intangible Assets Accumulated Amortization Excluding Goodwill

IntangibleAssetsAccumulatedAmortizationExcludingGoodwill

3506000000

usd

CY2021Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

10615000000

usd

CY2022

us-gaap

Indefinite Lived Intangible Assets Period Increase Decrease

IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease

-308000000

usd

CY2022

us-gaap

Finite Lived Intangible Assets Period Increase Decrease

FiniteLivedIntangibleAssetsPeriodIncreaseDecrease

308000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

806000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

370000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

311000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

258000000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

221000000

usd

CY2022

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-28000000

usd

CY2021

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-26000000

usd

CY2020

us-gaap

Defined Benefit Plan Recognized Net Gain Loss Due To Settlements1

DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1

-29000000

usd

CY2022Q4

elv

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

36000000

usd

CY2022Q4

elv

Claims Settlements To Be Paid From Other Benefit Assets

ClaimsSettlementsToBePaidFromOtherBenefitAssets

17000000

usd

CY2021Q4

elv

Defined Benefit Fair Value Due From Brokers

DefinedBenefitFairValueDueFromBrokers

48000000

usd

CY2021Q4

elv

Claims Settlements To Be Paid From Other Benefit Assets

ClaimsSettlementsToBePaidFromOtherBenefitAssets

29000000

usd

CY2022

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

275000000

usd

CY2021

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

241000000

usd

CY2020

us-gaap

Defined Contribution Plan Cost Recognized

DefinedContributionPlanCostRecognized

221000000

usd

CY2022

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, “Segment Information”), for the year ended December 31, 2022 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,847 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,157 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,282 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(21)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,834 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,149 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,261 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,067 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,552 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113,414 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(154)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(630)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(85)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(869)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,913 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81,165 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,467 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112,545 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,274 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71,463 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,997 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,362 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,052 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">186 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,636 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,515 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,446 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110,597 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,114 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,929 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">299 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,342 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,119 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,930 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">299 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,348 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2021 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,646 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,135 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,281 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,089 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">420 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70,670 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,638 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100,440 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(465)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,222)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,703)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,667 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,448 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,622 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,737 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,502 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,233 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,421 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,156 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,612 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,054 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,829 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,114 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,287 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,584 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,985 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,834 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,149 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,261 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,847 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,157 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">278 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,282 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt">A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2020 is as follows:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Commercial & Specialty Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Government Business</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, beginning of year</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,608 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,647 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, beginning of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(33)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, beginning of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,025 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,589 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,614 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Business combinations and purchase adjustments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">198 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">339 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net incurred medical claims:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,894 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,094 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years redundancies</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(375)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(262)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(637)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net incurred medical claims</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,519 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,650 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,457 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net payments attributable to:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current year medical claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,736 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,602 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,629 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prior years medical claims</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,527 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,165 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,692 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net payments</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24,263 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,767 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,291 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82,321 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net medical claims payable, end of year</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,281 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,089 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ceded medical claims payable, end of year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Gross medical claims payable, end of year</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,294 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,646 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,135 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>

CY2021Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

13282000000

usd

CY2021Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

21000000

usd

CY2021Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

13261000000

usd

CY2022Q4

elv

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

133000000

usd

CY2022

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

113414000000

usd

CY2022

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

869000000

usd

CY2022

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

112545000000

usd

CY2022

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

98997000000

usd

CY2022

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

11600000000

usd

CY2022

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

110597000000

usd

CY2022Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

15342000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

CY2022Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

15348000000

usd

CY2020Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

11135000000

usd

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

usd

CY2020Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

11089000000

usd

CY2021Q4

elv

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

420000000

usd

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

100440000000

usd

CY2021

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

1703000000

usd

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

98737000000

usd

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

88156000000

usd

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

8829000000

usd

CY2021

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

96985000000

usd

CY2021Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

13261000000

usd

CY2021Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

21000000

usd

CY2021Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

13282000000

usd

CY2019Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

usd

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

usd

CY2019Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8614000000

usd

CY2020Q4

elv

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

339000000

usd

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

85094000000

usd

CY2020

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

637000000

usd

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

usd

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

74629000000

usd

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

7692000000

usd

CY2020

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

82321000000

usd

CY2020Q4

elv

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

11089000000

usd

CY2020Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

46000000

usd

CY2020Q4

elv

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

11135000000

usd

CY2022

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

869000000

usd

CY2022

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

869000000

usd

CY2022

elv

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

859000000

usd

CY2021

elv

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

1429000000

usd

CY2020

elv

Favorable Unfavorable Developments By Changes In Trend Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInTrendFactorsAssumptions

599000000

usd

CY2022

elv

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

10000000

usd

CY2021

elv

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

274000000

usd

CY2020

elv

Favorable Unfavorable Developments By Changes In Completion Factors Assumptions

FavorableUnfavorableDevelopmentsByChangesInCompletionFactorsAssumptions

38000000

usd

CY2022

elv

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

869000000

usd

CY2021

elv

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

1703000000

usd

CY2020

elv

Favorable Unfavorable Developments By Changes In Total Assumptions

FavorableUnfavorableDevelopmentsByChangesInTotalAssumptions

637000000

usd

CY2022

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

112545000000

usd

CY2021

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

98737000000

usd

CY2020

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

84457000000

usd

CY2022

elv

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3942000000

usd

CY2021

elv

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3908000000

usd

CY2020

elv

Quality Improvement And Other Claims Expense

QualityImprovementAndOtherClaimsExpense

3588000000

usd

CY2022

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

116487000000

usd

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

usd

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

usd

CY2022Q4

us-gaap

Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet

305246000000

usd

CY2022Q4

us-gaap

Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net

ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet

289904000000

usd

CY2022Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

15342000000

usd

CY2022Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

6000000

usd

CY2022Q4

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

248000000

usd

CY2022Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

15596000000

usd

CY2022Q4

us-gaap

Long Term Debt

LongTermDebt

23849000000

usd

CY2021Q4

us-gaap

Long Term Debt

LongTermDebt

22756000000

usd

CY2022Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1500000000

usd

CY2021Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1599000000

usd

CY2022Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

22349000000

usd

CY2021Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

21157000000

usd

CY2022Q4

us-gaap

Debt Instrument Face Amount

DebtInstrumentFaceAmount

63000000

usd

CY2022Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

63000000

usd

CY2022

us-gaap

Debt Instrument Convertible Conversion Ratio1

DebtInstrumentConvertibleConversionRatio1

14.3238

CY2022Q4

us-gaap

Debt Instrument Convertible Conversion Price1

DebtInstrumentConvertibleConversionPrice1

69.8139

CY2022

us-gaap

Interest Paid

InterestPaid

878000000

usd

CY2021

us-gaap

Interest Paid

InterestPaid

822000000

usd

CY2020

us-gaap

Interest Paid

InterestPaid

794000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1500000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

1647000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

1650000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

746000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

1592000000

usd

CY2022Q4

us-gaap

Long Term Debt Maturities Repayments Of Principal After Year Five

LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

16714000000

usd

CY2022

us-gaap

Loss Contingency Accrual Payments

LossContingencyAccrualPayments

506000000

usd

CY2022Q4

us-gaap

Loss Contingency Estimate Of Possible Loss

LossContingencyEstimateOfPossibleLoss

596000000

usd

CY2022Q4

elv

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2022

us-gaap

Long Term Purchase Commitment Amount

LongTermPurchaseCommitmentAmount

761000000

usd

CY2022

us-gaap

Share Based Compensation

ShareBasedCompensation

264000000

usd

CY2021

us-gaap

Share Based Compensation

ShareBasedCompensation

255000000

usd

CY2020

us-gaap

Share Based Compensation

ShareBasedCompensation

283000000

usd

CY2022

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

66000000

usd

CY2021

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

65000000

usd

CY2020

us-gaap

Employee Service Share Based Compensation Tax Benefit From Compensation Expense

EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

74000000

usd

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

2900000

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

255.50

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

500000

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

452.67

CY2022

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

500000

shares

CY2022

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

242.79

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

339.20

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

2800000

shares

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

293.28

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y4M6D

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

622000000

usd

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

1600000

shares

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

239.89

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P5Y1M20D

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

448000000

usd

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1300000

shares

CY2021Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

299.65

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

600000

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

453.70

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

600000

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

301.89

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

100000

shares

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

347.73

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1200000

shares

CY2022Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

357.21

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0197

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0144

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0130

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2900

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3000

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2600

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0110

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0150

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0140

CY2022

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y1M6D

CY2021

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P5Y6M

CY2020

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y3M18D

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

116.92

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

79.91

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

54.05

CY2022

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

453.70

CY2021

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

317.70

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.37

CY2022Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2022-01-25

CY2022Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2022-03-10

CY2022Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2022-03-25

CY2022Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.28

CY2022Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

309000000

usd

CY2022Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2022-04-19

CY2022Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2022-06-10

CY2022Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2022-06-24

CY2022Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.28

CY2022Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

309000000

usd

CY2022Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2022-07-19

CY2022Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2022-09-09

CY2022Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2022-09-23

CY2022Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.28

CY2022Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

306000000

usd

CY2022Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2022-10-18

CY2022Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2022-12-05

CY2022Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2022-12-21

CY2022Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.28

CY2022Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

305000000

usd

CY2021Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-01-26

CY2021Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-03-10

CY2021Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-03-25

CY2021Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

277000000

usd

CY2021Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-04-20

CY2021Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-06-10

CY2021Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-06-25

CY2021Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

278000000

usd

CY2021Q3

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-07-20

CY2021Q3

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-09-10

CY2021Q3

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-09-24

CY2021Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q3

us-gaap

Payments Of Dividends

PaymentsOfDividends

276000000

usd

CY2021Q4

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2021-10-19

CY2021Q4

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2021-12-03

CY2021Q4

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2021-12-21

CY2021Q4

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.13

CY2021Q4

us-gaap

Payments Of Dividends

PaymentsOfDividends

273000000

usd

CY2021Q1

elv

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

usd

CY2022

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

4800000

shares

CY2021

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

5100000

shares

CY2022

elv

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

478.99

CY2021

elv

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

371.46

CY2022

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

2316000000

usd

CY2021

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

1900000000

usd

CY2022Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

1876000000

usd

CY2021Q4

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

4192000000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-178000000

usd

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

usd

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-809000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-110000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

154000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-2336000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-330000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

446000000

usd

CY2022

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

3000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

-1000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2022

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-11000000

usd

CY2021

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

-2000000

usd

CY2020

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest

0

usd

CY2022Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-2503000000

usd

CY2021Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-178000000

usd

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

150000000

usd

CY2022

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

128867000000

usd

CY2021

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

113149000000

usd

CY2020

us-gaap

Direct Premiums Earned

DirectPremiumsEarned

100832000000

usd

CY2022

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

4426000000

usd

CY2021

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

4298000000

usd

CY2020

us-gaap

Assumed Premiums Earned

AssumedPremiumsEarned

3356000000

usd

CY2022

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

64000000

usd

CY2021

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

74000000

usd

CY2020

us-gaap

Ceded Premiums Earned

CededPremiumsEarned

79000000

usd

CY2022

us-gaap

Premiums Earned Net

PremiumsEarnedNet

133229000000

usd

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

usd

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

usd

CY2022

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.033

CY2021

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.037

CY2020

us-gaap

Premiums Percentage Assumed To Net

PremiumsPercentageAssumedToNet

0.032

CY2022

us-gaap

Premiums Earned Net

PremiumsEarnedNet

133229000000

usd

CY2021

us-gaap

Premiums Earned Net

PremiumsEarnedNet

117373000000

usd

CY2020

us-gaap

Premiums Earned Net

PremiumsEarnedNet

104109000000

usd

CY2022

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

112809000000

usd

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

99007000000

usd

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Gross

PolicyholderBenefitsAndClaimsIncurredGross

85168000000

usd

CY2022

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

3730000000

usd

CY2021

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

3719000000

usd

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Assumed

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed

2967000000

usd

CY2022

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

52000000

usd

CY2021

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

81000000

usd

CY2020

us-gaap

Reinsurance Effect On Claims And Benefits Incurred Amount Ceded

ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded

90000000

usd

CY2022

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

116487000000

usd

CY2021

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

102645000000

usd

CY2020

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

88045000000

usd

CY2022Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

604000000

usd

CY2021Q4

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

628000000

usd

CY2022Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

181000000

usd

CY2021Q4

us-gaap

Operating Lease Liability Current

OperatingLeaseLiabilityCurrent

133000000

usd

CY2022Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

751000000

usd

CY2021Q4

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

864000000

usd

CY2022

us-gaap

Operating Lease Cost

OperatingLeaseCost

143000000

usd

CY2021

us-gaap

Operating Lease Cost

OperatingLeaseCost

261000000

usd

CY2020

us-gaap

Operating Lease Cost

OperatingLeaseCost

438000000

usd

CY2022

elv

Short Term And Variable Lease Cost

ShortTermAndVariableLeaseCost

35000000

usd

CY2021

elv

Short Term And Variable Lease Cost

ShortTermAndVariableLeaseCost

45000000

usd

CY2020

elv

Short Term And Variable Lease Cost

ShortTermAndVariableLeaseCost

50000000

usd

CY2022

us-gaap

Sublease Income

SubleaseIncome

3000000

usd

CY2021

us-gaap

Sublease Income

SubleaseIncome

4000000

usd

CY2020

us-gaap

Sublease Income

SubleaseIncome

9000000

usd

CY2022

us-gaap

Lease Cost

LeaseCost

175000000

usd

CY2021

us-gaap

Lease Cost

LeaseCost

302000000

usd

CY2020

us-gaap

Lease Cost

LeaseCost

479000000

usd

CY2022

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

34000000

usd

CY2021

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

136000000

usd

CY2020

us-gaap

Operating Lease Impairment Loss

OperatingLeaseImpairmentLoss

258000000

usd

CY2022

us-gaap

Operating Lease Payments

OperatingLeasePayments

204000000

usd

CY2021

us-gaap

Operating Lease Payments

OperatingLeasePayments

198000000

usd

CY2022

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

113000000

usd

CY2021

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

334000000

usd

CY2022Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2021Q4

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2022Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0298

CY2021Q4

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0269

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

206000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

179000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

145000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

111000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

77000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

310000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

1028000000

usd

CY2022Q4

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

96000000

usd

CY2022Q4

us-gaap

Operating Lease Liability

OperatingLeaseLiability

932000000

usd

CY2022

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

240000000.0

shares

CY2021

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

243800000

shares

CY2020

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

250800000

shares

CY2022

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

2800000

shares

CY2021

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3000000.0

shares

CY2020

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3500000

shares

CY2022

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

242800000

shares

CY2021

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

246800000

shares

CY2020

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

254300000

shares

CY2022

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

400000

shares

CY2021

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

200000

shares

CY2020

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1200000

shares

CY2022

elv

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2021

elv

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2020

elv

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2022

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2022

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

155660000000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

8452000000

usd

CY2022

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

784000000

usd

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

7489000000

usd

CY2021

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

668000000

usd

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

usd

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

usd

CY2020

us-gaap

Other Depreciation And Amortization

OtherDepreciationAndAmortization

638000000

usd

CY2022

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

155660000000

usd

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

usd

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

usd

CY2022

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

155660000000

usd

CY2021

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

136943000000

usd

CY2020

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

120808000000

usd

CY2022

us-gaap

Net Investment Income

NetInvestmentIncome

1485000000

usd

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

usd

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

usd

CY2022

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

-550000000

usd

CY2021

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

318000000

usd

CY2020

elv

Net Gains Losses On Financial Instruments

NetGainsLossesOnFinancialInstruments

182000000

usd

CY2022

us-gaap

Revenues

156595000000

usd

CY2021

us-gaap

Revenues

138639000000

usd

CY2020

us-gaap

Revenues

121867000000

usd

CY2022

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7769000000

usd

CY2021

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7925000000

usd

CY2020

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

6238000000

usd

CY2022

us-gaap

Net Investment Income

NetInvestmentIncome

1485000000

usd

CY2021

us-gaap

Net Investment Income

NetInvestmentIncome

1378000000

usd

CY2020

us-gaap

Net Investment Income

NetInvestmentIncome

877000000

usd

CY2022

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

-550000000

usd

CY2021

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

318000000

usd

CY2020

elv

Net Losses Gains On Financial Instruments

NetLossesGainsOnFinancialInstruments

182000000

usd

CY2022

us-gaap

Interest Expense

InterestExpense

851000000

usd

CY2021

us-gaap

Interest Expense

InterestExpense

798000000

usd

CY2020

us-gaap

Interest Expense

InterestExpense

784000000

usd

CY2022

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

767000000

usd

CY2021

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

441000000

usd

CY2020

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

361000000

usd

CY2022

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

usd

CY2021

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-21000000

usd

CY2020

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-36000000

usd

CY2022

us-gaap

Operating Income Loss

OperatingIncomeLoss

8452000000

usd

CY2021

us-gaap

Operating Income Loss

OperatingIncomeLoss

7489000000

usd

CY2020

us-gaap

Operating Income Loss

OperatingIncomeLoss

6360000000

usd

CY2022Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

7900000000

usd

CY2021Q4

us-gaap

Statutory Accounting Practices Statutory Capital And Surplus Required

StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired

6962000000

usd

CY2022

us-gaap

Statutory Accounting Practices Dividends Paid With Approval Of Regulatory Agency

StatutoryAccountingPracticesDividendsPaidWithApprovalOfRegulatoryAgency

3097000000

usd

CY2022Q4

elv

Estimated Future Dividend Payments

EstimatedFutureDividendPayments

3500000000

usd

Name	View Source	Status
0001156039-23-000007-index-headers.html	Edgar Link	pending
0001156039-23-000007-index.html	Edgar Link	pending
0001156039-23-000007.txt	Edgar Link	pending
0001156039-23-000007-xbrl.zip	Edgar Link	pending
elv-20221231.htm	Edgar Link	pending
elv-20221231.xsd	Edgar Link	pending
elv-20221231_g1.jpg	Edgar Link	pending
elv-20221231_g2.jpg	Edgar Link	pending
exhibit101-20221231forform.htm	Edgar Link	pending
exhibit1011-primarybluecro.htm	Edgar Link	pending
exhibit1012-primaryblueshi.htm	Edgar Link	pending
exhibit21-20221231forform1.htm	Edgar Link	pending
exhibit23-20221231forform1.htm	Edgar Link	pending
exhibit311-20221231for10xk.htm	Edgar Link	pending
exhibit312-20221231for10xk.htm	Edgar Link	pending
exhibit321-20221231for10xk.htm	Edgar Link	pending
exhibit322-20221231for10xk.htm	Edgar Link	pending
exhibit47-20221231forform1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
elv-20221231_cal.xml	Edgar Link	unprocessable
elv-20221231_def.xml	Edgar Link	unprocessable
elv-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
elv-20221231_htm.xml	Edgar Link	completed
elv-20221231_lab.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2023 Q1 Form 10-K Financial Statement

#000115603923000007 Filed on February 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2023 Q1 Form 10-K Financial Statement

#000115603923000007 Filed on February 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv